In keeping with the observed anti-neoplastic capacity we demonstrate that Vandetanib treatment attenuates AKT and STAT3 activity, downstream elements of aberrant signaling pathways in medulloblastoma [26–30]. The gene discussed is STAT3; the disease is medulloblastoma.